American Association for Cancer Research (AACR), 2023.
سنة النشر:
2023
الوصف:
Supplementary Table 1: Clinical data on samples stained for HDAC8 expression. S1) HDAC expression levels in melanoma cells S2) Cell lines that are resistant to BRAF inhibitors have upregulated c-Jun protein expression S3) Inhibiting HDAC6 does not resensitize BRAF/MEK resistant cells to BRAF inhibitors S4) BRAF/MEK inhibitor withdrawal decreases HDAC8 expression over time S5) Knocking down or elevating HDAC8 levels does not change cell proliferation S6) Expression of HDAC8 increased ERK activity and resistance upon treatment with BRAF-MEK inhibitors S7) Knocking down HDAC8 in BRAFi naïve cells increased apoptosis and BIM expression while decreasing ERK activity after BRAFi activity. S8) HDAC8 expression increases baseline RTK signaling S9) Inhibiting MET or FGFR3 partially resensitizes HDAC8 expressing cells to BRAF inhibitors S10) HDAC8 expression increases baseline c-Jun, p53, AKT and HSP60 signaling S11) Inhibiting c-Jun resensitizes HDAC8 expressing cells to a BRAF inhibitor S12) Protein sequences of c-Jun acetyl mutants S13) Acetylation-deficient c-JUN at residue 273 increases melanoma cell survival following BRAF inhibition S14) Acetylation-deficient c-Jun at residue 273 increases p53, Akt 1/2/3, STAT3, WNK1 and HSP60 S15) Acetylation-deficient c-JUN at residue 273 increases baseline EGFR signaling
